Drugs News and Research

RSS

Lack of grey matter linked to schizophrenia and bipolar disorder

A research study led by scientists from the Gregorio Marañón University Hospital in Madrid and the Network of Centres for Biomedical Research in Mental Health Networks (CIBERSAM) shows that adolescents experiencing a first outbreak of psychosis have lower levels of grey matter in their brains than healthy teenagers. Strangely, this change was seen in patients suffering from various psychoses, including bipolar illness and schizophrenia.

19 Jan 2009

Healthcare among public's top priorities for economic stimulus

The public ranks action on health care highly as part of efforts to stem the impact of the economic recession and also views reforming health care as one of the top priorities for President-elect Obama and Congress, according to a new national survey conducted by researchers from the Kaiser Family Foundation and the Harvard School of Public Health.

19 Jan 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

New FDA guidelines for foods and feeds

The U.S. Food and Drug Administration has issued three guidances designed to help ensure the safety of FDA-regulated products in the supply chain.

19 Jan 2009

FDA issues final guidance on genetically engineered animal regulation

The U.S. Food and Drug Administration has issued a final guidance for industry on the regulation of genetically engineered (GE) animals under the new animal drug provisions of the Federal Food, Drug and Cosmetic Act (FFDCA).

19 Jan 2009

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

American pharmaceutical giant Eli Lilly and Company today agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration (FDA), the Department of Justice announced today.

19 Jan 2009

E. coli persists against antibiotics through HipA-induced dormancy

Bacteria hunker down and survive antibiotic attack when a protein flips a chemical switch that throws them into a dormant state until treatment abates, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan.16 edition of Science.

19 Jan 2009

FDA approves RiaSTAP for bleeding in patients with congenital fibrinogen deficiency

The U.S. Food and Drug Administration has licensed RiaSTAP, an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as congenital fibrinogen deficiency. Without treatment, these patients are at risk of potentially life-threatening bleeding.

18 Jan 2009

Nanotubes sniff out cancer agents in living cells

A multidisciplinary team at the Massachusetts Institute of Technology (MIT) has developed carbon nanotubes that can be used as sensors for cancer drugs and other DNA-damaging agents inside living cells. The sensors, made of carbon nanotubes wrapped in DNA, can detect chemotherapy drugs such as cisplatin as well as environmental toxins and free radicals that damage DNA.

18 Jan 2009

Artificial antibody delivers nanoparticles to tumors

Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on this targeting ability, using a modified anti-EGFR antibody to delivery nanoparticles into tumor cells.

18 Jan 2009

Polymer nanoparticle for oral anticancer drug delivery

One of the problems that cancer patients face is that many of the most potent anticancer therapies can be administered only by injection, which means that cancer patients must travel to receive their medication. But thanks to a new type of nanoparticle developed by researchers at the Johns Hopkins University School of Medicine, future cancer patients may be able to receive their medication in pill form.

18 Jan 2009

Too much coffee can lead to hallucinations

According to a study by researchers at Durham University people with a higher caffeine intake, from coffee, tea and caffeinated energy drinks, are more likely to experience hallucinatory experiences such as hearing voices and seeing things that are not there.

18 Jan 2009

The retina reveals deadly secrets of malaria

Looking at the retina in the eyes of patients with cerebral malaria has provided scientists with a vital insight into why malaria infection in the brain is so deadly.

15 Jan 2009

Discovery of protein that amplifies cell death

Scientists at Albert Einstein College of Medicine of Yeshiva University have identified a small intracellular protein that helps cells commit suicide.

15 Jan 2009

New model system may better explain regulation of body weight

A new mathematical model of the physiological regulation of body weight suggests a potential mechanism underlying the difficulty of losing weight, one that includes aspects of two competing hypotheses of weight regulation.

15 Jan 2009

Discovery of link between genetic defect on chromosome 15 and epilepsy

In a research published in the advanced online publication of the scientific magazine Nature Genetics, researchers have identified a genetic defect for common epilepsies on chromosome 15.

15 Jan 2009

Discovery of protein that amplifies cell death

Scientists at Albert Einstein College of Medicine of Yeshiva University have identified a small intracellular protein that helps cells commit suicide.

15 Jan 2009

FDA launches pilot program to improve drug safety and active drug ingredients produced outside U.S.

The U.S. Food and Drug Administration today announced the launch of a voluntary pilot program that would help promote the safety of drugs and active drug ingredients produced outside the United States.

14 Jan 2009

Theraputic target for prostate cancer

The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.

14 Jan 2009

Electrical stimulation of the brain offers hope for Parkinson's sufferers

Electrical stimulation of the brain -- a treatment in which a pacemaker-like device sends pulses to electrodes implanted in the brain -- is riskier than drug therapy but may hold significant benefits for those with Parkinson's disease who no longer respond well to medication alone.

14 Jan 2009